Growth controls connect: Interactions between c-myc and the tuberous sclerosis complex-mTOR pathway

Cell Cycle

Volumn 8, Issue 9, 2009, Pages 1344-1351

  Schmidt, Emmett V ^a   Ravitz, Michael J ^a   Chen, Li ^a   Lynch, Mary ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

c Myc; Rapamycin; Translation initiation regulation; Tuberin

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; TAMOXIFEN; TUBERIN;

CANCER GROWTH; CELL GROWTH; CELL INTERACTION; EMBRYO; GENE AMPLIFICATION; GENE EXPRESSION; GENE INACTIVATION; GENE INTERACTION; GENETIC TRANSCRIPTION; GROWTH REGULATION; HUMAN; MOUSE; NEOPLASM; NONHUMAN; ONCOGENE C MYC; ONCOGENE MYC; PROMOTER REGION; PROTEIN DEPLETION; RAT; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE;

EID: 65949122722     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.9.8215     Document Type: Review

References (114)

1. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134:703-707
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70. (Pubitemid 30046295)
3. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 2002; 22:2111-2123
4. Mitchison JM. The biology of the cell cycle. Cambridge: Harvard University Press 1971.
5. Hartwell LH. Genetic control of the cell division cycle in yeast II. Genes controlling DNA replication and its initiation. J Mol Biol 1971; 59:183-194
6. Baserga R. The Biology of Cell Reproduction. Cambridge: Harvard University Press 1985.
7. Rosenwald IB, Rhoads DB, Callanan LD, Isselbacher KJ, Schmidt EV. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2alpha in response to growth induction by c-myc. Proc Natl Acad Sci USA 1993; 90:6175-6178 (Pubitemid 23191477)
8. Schmidt EV. The role of c-myc in cellular growth control. Oncogene 1999; 18:2988-2996 (Pubitemid 29276538)
9. Gallant P, Shiio Y, Cheng PF, Parkhurst SM, Eisenman RN. Myc and Max homologs in Drosophila. Science 1996; 274:1523-1527 (Pubitemid 26403927)
10. Johnston LA, Prober DA, Edgar BA, Eisenman RN, Gallant P. Drosophila myc regulates cellular growth during development. Cell 1999; 98:779-790
11. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 1997; 8:1039-1048 (Pubitemid 27433292)
12. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007; 12:108-113 (Pubitemid 47199124)
13. Arabi A, Wu S, Ridderstrale K, Bierhoff H, Shiue C, Fatyol K, et al. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol 2005; 7:303-310 (Pubitemid 40331132)
14. Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 2005; 7:311-318 (Pubitemid 40331133)
15. Grewal SS, Li L, Orian A, Eisenman RN, Edgar BA. Myc-dependent regulation of ribosomal RNA synthesis during Drosophila development. Nat Cell Biol 2005; 7:295-302. (Pubitemid 40331131)
16. Dang CV. http://www.myccancergene.org/. 2005.
17. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 2003; 4:69.
18. Schmidt EV. The role of c-myc in regulation of translation initiation. Oncogene 2004; 23:3217-3221 (Pubitemid 38638833)
19. Gomez-Roman N, Grandori C, Eisenman RN, White RJ. Direct activation of RNA polymerase III transcription by c-Myc. Nature 2003; 421:290-294 (Pubitemid 36139136)
20. Rosenwald IB. The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene 2004; 23:3230-3247 (Pubitemid 38638835)
21. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E-from translation to transformation. Oncogene 2004; 23:3172-3179
22. Holland EC, Sonenberg N, Pandolfi PP, Thomas G. Signaling control of mRNA translation in cancer pathogenesis. Oncogene 2004; 23:3138-3144 (Pubitemid 38638825)
23. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23:3189-3199 (Pubitemid 38638830)
24. De Benedetti A, Rhoads RE. Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. Proc Natl Acad Sci USA 1990; 87:8212-8216 (Pubitemid 20373060)
25. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 1990; 345:544-547 (Pubitemid 20178912)
26. Asano K, Merrick WC, Hershey JW. The translation initiation factor eIF3-p48 subunit is encoded by int-6, a site of frequent integration by the mouse mammary tumor virus genome. J Biol Chem 1997; 272:23477-23480 (Pubitemid 27410912)
27. Watkins SJ, Norbury CJ. Cell cycle-related variation in subcellular localization of eIF3e/INT6 in human fibroblasts. Cell Prolif 2004; 37:149-160 (Pubitemid 38429326)
28. Kim JW, Zeller KI, Wang Y, Jegga AG, Aronow BJ, O'Donnell KA, et al. Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol 2004; 24:5923-5936
29. Proud CG. Role of mTOR signalling in the control of translation initiation and elongation by nutrients. Curr Top Microbiol Immunol 2004; 279:215-244
30. Oldham S, Montagne J, Radimerski T, Thomas G, Hafen E. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev 2000; 14:2689-2694 (Pubitemid 32531195)
31. Radimerski T, Montagne J, Hemmings-Mieszczak M, Thomas G. Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev 2002; 16:2627-2632
32. Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European Chromosome 16 Tuberous Sclerosis Consortium. Cell 1993; 75:1305-1315
33. Wienecke R, Konig A, DeClue JE. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J Biol Chem 1995; 270:16409-16414
34. Potter CJ, Huang H, Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation and organ size. Cell 2001; 105:357-368 (Pubitemid 32455342)
35. Gao X, Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 2001; 15:1383-1392 (Pubitemid 32524645)
36. Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 2001; 105:345-355 (Pubitemid 32455341)
37. Rosner M, Hofer K, Kubista M, Hengstschlager M. Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38. Oncogene 2003; 22:4786-4798 (Pubitemid 36981267)
38. Ravitz MJ, Chen L, Lynch M, Schmidt EV. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation. Cancer Res 2007; 67:11209-11217 (Pubitemid 350248546)
39. Olsson PG, Schofield JN, Edwards YH, Frischauf AM. Expression and differential splicing of the mouse TSC2 homolog. Mamm Genome 1996; 7:212-215 (Pubitemid 126426600)
40. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. Renal carcinogenesis, hepatic hemangiomatosis and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999; 59:1206-1211 (Pubitemid 29136248)
41. Fukuda T, Kobayashi T, Yasui H, Tsutsumi M, Konishi Y, Hino O. Distribution of Tsc2 protein in various normal rat tissues and renal tumours of Tsc2 mutant (Eker) rat detected by immunohistochemistry. Virchows Arch 1999; 434:341-350 (Pubitemid 29201837)
42. Fukuda T, Kobayashi T, Momose S, Yasui H, Hino O. Distribution of Tsc1 protein detected by immunohistochemistry in various normal rat tissues and the renal carcinomas of Eker rat: detection of limited colocalization with Tsc1 and Tsc2 gene products in vivo. Lab Invest 2000; 80:1347-1359
43. Wienecke R, Maize JC Jr, Reed JA, de Gunzburg J, Yeung RS, DeClue JE. Expression of the TSC2 product tuberin and its target Rap1 in normal human tissues. Am J Pathol 1997; 150:43-50. (Pubitemid 27027094)
44. Imai K, Sarker AH, Akiyama K, Ikeda S, Yao M, Tsutsui K, et al. Genomic structure and sequence of a human homologue (NTHL1/NTH1) of Escherichia coli endonuclease III with those of the adjacent parts of TSC2 and SLC9A3R2 genes. Gene 1998; 222:287-295
45. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004; 101:6062-6067
46. Kobayashi T, Urakami S, Cheadle JP, Aspinwall R, Harris P, Sampson JR, et al. Identification of a leader exon and a core promoter for the rat tuberous sclerosis 2 (Tsc2) gene and structural comparison with the human homolog. Mamm Genome 1997; 8:554-558
47. Loots GG, Ovcharenko I, Pachter L, Dubchak I, Rubin EM. rVista for comparative sequence-based discovery of functional transcription factor binding sites. Genome Res 2002; 12:832-839 (Pubitemid 34546471)
48. Honda S, Kobayashi T, Kajino K, Urakami S, Igawa M, Hino O. Ets protein Elf-1 bidirectionally suppresses transcriptional activities of the tumor suppressor Tsc2 gene and the repair-related Nth1 gene. Mol Carcinog 2003; 37:122-129 (Pubitemid 36951357)
49. Wienecke R, Guha A, Maize JC Jr, Heideman RL, DeClue JE, Gutmann DH. Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas. Ann Neurol 1997; 42:230-235 (Pubitemid 27340469)
50. Kataoka K, Fujimoto K, Ito D, Koizumi M, Toyoda E, Mori T, et al. Expression and prognostic value of tuberous sclerosis complex 2 gene product tuberin in human pancreatic cancer. Surgery 2005; 138:450-455
51. Chakraborty S, Mohiyuddin SM, Gopinath KS, Kumar A. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC cancer 2008; 8:163.
52. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005; 102:8204-8209 (Pubitemid 40800067)
53. Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, et al. The regulation of AMPK beta1, TSC2 and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 2007; 67:3043-3053
54. Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res 2008; 68:5326-5334
55. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002; 16:1472-1487 (Pubitemid 34686329)
56. Information NCfB. http://www.ncbi.nlm.nih.gov/. 2006.
57. Yamashita R, Suzuki Y, Wakaguri H, Tsuritani K, Nakai K, Sugano S. DBTSS: DataBase of Human Transcription Start Sites, progress report 2006. Nucleic Acids Res 2006; 34:86-89
58. Center ABC. http://grid.abcc.ncifcrf.gov/promoters.php. 2006.
59. Loots GG, Ovcharenko I. rVISTA 2.0: evolutionary analysis of transcription factor binding sites. Nucleic Acids Res 2004; 32:217-221
60. Kleine-Kohlbrecher D, Adhikary S, Eilers M. Mechanisms of transcriptional repression by Myc. Curr Top Microbiol Immunol 2006; 302:51-62. (Pubitemid 43268503)
61. Hurlin PJ, Queva C, Eisenman RN. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev 1997; 11:44-58. (Pubitemid 27043823)
62. Sankar N, Baluchamy S, Kadeppagari RK, Singhal G, Weitzman S, Thimmapaya B. p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc. Oncogene 2008; 27:5717-5728
63. Kurland JF, Tansey WP. Myc-mediated transcriptional repression by recruitment of histone deacetylase. Cancer Res 2008; 68:3624-3629
64. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, Schmidt EV. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Molecular & Cellular Biology 1993; 13:7358-7363 (Pubitemid 23354259)
65. Nelsen CJ, Rickheim DG, Tucker MM, Hansen LK, Albrecht JH. Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J Biol Chem 2003; 278:3656-3663 (Pubitemid 36801089)
66. Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3'UTR. J Cell Biol 2005; 169:245-256 (Pubitemid 40656563)
67. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem 2005; 280:10964-10973 (Pubitemid 40418398)
68. Nanbru C, Lafon I, Audigier S, Gensac MC, Vagner S, Huez G, et al. Alternative translation of the proto-oncogene c-myc by an internal ribosome entry site. J Biol Chem 1997; 272:32061-32066
69. Stoneley M, Paulin FE, Le Quesne JP, Chappell SA, Willis AE. C-Myc 5′ untranslated region contains an internal ribosome entry segment. Oncogene 1998; 16:423-428 (Pubitemid 28052297)
70. Stoneley M, Chappell SA, Jopling CL, Dickens M, MacFarlane M, Willis AE. c-Myc protein synthesis is initiated from the internal ribosome entry segment during apoptosis. Mol Cell Biol 2000; 20:1162-1169 (Pubitemid 30069236)
71. Hann SR, King MW, Bentley DL, Anderson CW, Eisenman RN. A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas. Cell 1988; 52:185-195 (Pubitemid 18042856)
72. West MJ, Stoneley M, Willis AE. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene 1998; 17:769-780 (Pubitemid 28412498)
73. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004; 279:2737-2746
74. Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998; 54:815-824
75. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-337
76. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, et al. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 2008; 105:10853-10858
77. Green AJ, Smith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 1994; 6:193-196 (Pubitemid 24188602)
78. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang JA, Kumaki F, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004; 101:17462-17467
79. Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S, et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 2002; 47:20-28
80. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000; 97:6085-6090 (Pubitemid 30367527)
81. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998; 62:810-815 (Pubitemid 28194322)
82. Henske EP, Neumann HP, Scheithauer BW, Herbst EW, Short MP, Kwiatkowski DJ. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer 1995; 13:295-298
83. Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996; 59:400-406
84. Longa L, Scolari F, Brusco A, Carbonara C, Polidoro S, Valzorio B, et al. A large TSC2 and PKD1 gene deletion is associated with renal and extrarenal signs of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1997; 12:1900-1907.
85. Parry L, Maynard JH, Patel A, Clifford SC, Morrissey C, Maher ER, et al. Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. Br J Cancer 2001; 85:1226-1230
86. Karbowniczek M, Yu J, Henske EP. Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am J Pathol 2003; 162:491-500. (Pubitemid 36267856)
87. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121:179-193 (Pubitemid 40546387)
88. Jozwiak J. Hamartin and tuberin: Working together for tumour suppression. Int J Cancer 2006; 118:1-5.
89. Jozwiak J, Jozwiak S. Giant cells: contradiction to two-hit model of tuber formation? Cell Mol Neurobiol 2005; 25:795-805.
90. Henske EP, Wessner LL, Golden J, Scheithauer BW, Vortmeyer AO, Zhuang Z, et al. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol 1997; 151:1639-1647
91. Yeung RS, Katsetos CD, Klein-Szanto A. Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis. Am J Pathol 1997; 151:1477-1486 (Pubitemid 27479778)
92. Al-Saleem T, Wessner LL, Scheithauer BW, Patterson K, Roach ES, Dreyer SJ, et al. Malignant tumors of the kidney, brain and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 1998; 83:2208-2216
93. Przkora R, Meyer-Puttlitz B, Schmitt O, Berthold F, Nothen M, Krauss J, et al. Analysis of the TSC2 gene in human medulloblastoma. Acta Neuropathol (Berl) 2001; 102:380-384
94. +/- cells. Oncogene 2002; 21:4050-4059 (Pubitemid 34679246)
95. Mizuguchi M, Mori M, Nozaki Y, Momoi MY, Itoh M, Takashima S, et al. Absence of allelic loss in cytomegalic neurons of cortical tuber in the Eker rat model of tuberous sclerosis. Acta Neuropathol 2004; 107:47-52.
96. Lee EY, To H, Shew JY, Bookstein R, Scully P, Lee WH. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 1988; 241:218-221
97. Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 2003; 63:7652-7656 (Pubitemid 37466691)
98. Hornigold N, Devlin J, Davies AM, Aveyard JS, Habuchi T, Knowles MA. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 1999; 18:2657-2661 (Pubitemid 29216689)
99. Habuchi T, Devlin J, Elder PA, Knowles MA. Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene 1995; 11:1671-1674
100. Lininger RA, Park WS, Man YG, Pham T, MacGrogan G, Zhuang Z, et al. LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast. Hum Pathol 1998; 29:1113-1118
101. Takamochi K, Ogura T, Suzuki K, Kawasaki H, Kurashima Y, Yokose T, et al. Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. Am J Pathol 2001; 159:1941-1948.
102. Suzuki K, Ogura T, Yokose T, Nagai K, Mukai K, Kodama T, et al. Loss of heterozygosity in the tuberous sclerosis gene associated regions in adenocarcinoma of the lung accompanied by multiple atypical adenomatous hyperplasia. Int J Cancer 1998; 79:384-389
103. Francalanci P, Diomedi-Camassei F, Purificato C, Santorelli FM, Giannotti A, Dominici C, et al. Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. Am J Surg Pathol 2003; 27:1386-1389
104. Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WL, Bax NM, Ariyurek Y, Hermans CJ, et al. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr 1999; 158:284-287
105. Jiang WG, Sampson J, Martin TA, Lee-Jones L, Watkins G, Douglas-Jones A, et al. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 2005; 41:1628-1636
106. Schuldiner O, Benvenisty N. A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors. Oncogene 2001; 20:4984-4994 (Pubitemid 32769788)
107. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, et al. Genomic targets of the human c-Myc protein. Genes Dev 2003; 17:1115-1129
108. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 2003; 100:8164-8169 (Pubitemid 36842516)
109. Guccione E, Martinato F, Finocchiaro G, Luzi L, Tizzoni L, Dall' Olio V, et al. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 2006; 8:764-770
110. Murthy V, Han S, Beauchamp RL, Smith N, Haddad LA, Ito N, et al. Pam and its ortholog highwire interact with and may negatively regulate the TSC1.TSC2 complex. J Biol Chem 2004; 279:1351-1358
111. Han S, Witt RM, Santos TM, Polizzano C, Sabatini BL, Ramesh V. Pam (Protein associated with Myc) functions as an E3 ubiquitin ligase and regulates TSC/mTOR signaling. Cell Signal 2008; 20:1084-1091
112. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, et al. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci USA 2002; 99:4465-4470
113. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992; 69:1227-1236
114. Ravitz MJ, Yan S, Dolce C, Kinniburgh AJ, Wenner CE. Differential regulation of p27 and cyclin D1 by TGFbeta and EGF in C3H 10T1/2 mouse fibroblasts. J Cell Physiol 1996; 168:510-520 (Pubitemid 26302857)